Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WESTBOROUGH, Mass., May 9, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company’s Chief Development Officer, Pamela Pavco, Ph.D., will be presenting at IBC’s 15th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference. The TIDES Summit is prominently known as the premier meeting place for the oligonucleotide and peptide discovery, development and manufacturing industries.
On Wednesday, May 15, 2013 at 4:15pm EDT, Dr. Pavco will deliver a speaker presentation entitled “Clinical Development of RXI-109 to Reduce Dermal Scarring”, during the Clinical Progress of Oligonucleotide Therapeutics session. Dr. Pavco’s presentation will be available on the Company’s website.
This conference is being held May 12-15, 2013 at the Hynes Convention Center, Boston, MA. For more information visit: http://www.ibclifesciences.com/TIDES
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi’s first RNAi product candidate, RXI-109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation’s products and technologies. Forward-looking statements about expectations and development plans of RXi’s products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation
Help employers find you! Check out all the jobs and post your resume.
